Weight Loss Injections: Why Middle-Class Women Are Turning to Mounjaro & Ozempic

A growing body of evidence suggests that weight-loss medications, particularly GLP-1 receptor agonists like Ozempic and Mounjaro, are not being equitably distributed, with women and individuals in middle-class socioeconomic brackets dominating uptake. This trend raises questions about access, affordability, and the potential for exacerbating existing health disparities.

New analysis, by the Health Foundation, reveals that approximately 79% of private prescriptions for these drugs are written for women. The highest concentration of prescriptions is found among individuals aged 30 to 49, with a sharp decline in usage after age 60. This demographic pattern is particularly notable given that obesity rates are often higher in more deprived communities, where access to these medications is significantly lower.

The increasing popularity of these medications is evident in personal accounts. Olivia Falcon, a 51-year-old woman, describes her experience with GLP-1 medications, beginning with Ozempic in April 2023. Despite not being clinically obese, Falcon found herself struggling with weight gain, lower back pain, elevated cholesterol, and prediabetes. After traditional lifestyle interventions proved insufficient, she turned to Ozempic, and later Mounjaro, under medical supervision, reporting significant improvements in her health and well-being. She currently spends £200 monthly on a prescription for Mounjaro.

However, the path hasn’t been without side effects. Falcon experienced significant hair loss, prompting her to undergo a hair transplant. She emphasizes the importance of regular medical check-ups and blood testing while on these medications, noting a reported case of pancreatitis in an acquaintance, highlighting potential risks.

The experience of Susannah Jowitt, a writer, offers a contrasting perspective. While acknowledging the allure of these medications, she expresses concerns about their long-term sustainability and potential for creating a cycle of dependence. Jowitt highlights the financial burden, estimating a monthly cost of £280 or more, and questions the ethical implications of making weight loss accessible primarily to those who can afford it. She also points out that weight regained after discontinuing the medication is likely to be primarily fat, rather than the muscle loss experienced during treatment, potentially worsening metabolic health.

The trend is further underscored by observations from Katie Glass, who notes that friends are often reluctant to discuss their use of weight-loss jabs openly, attributing their weight loss to other factors like changes in appetite or increased exercise. This secrecy suggests a degree of social stigma or discomfort surrounding the use of these medications, despite their growing prevalence.

Data from the Health Foundation indicates that individuals in the most deprived areas are approximately one-third less likely to receive these medications compared to those in the least deprived areas, despite experiencing twice the prevalence of obesity. Among 30 to 49-year-olds in the most deprived areas, only 45% began treatment with a BMI of 35 or above, compared to 30% in the least deprived areas. This suggests that individuals in more affluent communities may be accessing these medications at lower BMI levels, potentially for cosmetic or preventative reasons, rather than solely for managing obesity-related health risks.

Samantha Field, a senior fellow at the Health Foundation, emphasizes the need for equitable access to these medications, stating, “The groups bearing the greatest burden of obesity are seeking GLP-1 treatments less frequently, and often at higher BMIs.” She urges the National Health Service (NHS) to consider these findings as it rolls out these medications publicly, ensuring they reach those most in need.

The long-term effects of GLP-1 medications remain under investigation. While initial studies suggest potential benefits beyond weight loss, including anti-inflammatory effects and improvements in gut health, cognitive function, and heart health, further research is needed to fully understand their long-term safety, and efficacy. The potential for side effects, such as nausea, constipation, diarrhea, and, as reported by Falcon, hair loss, also warrants careful consideration.

The current landscape of weight-loss medication access highlights a complex interplay of socioeconomic factors, individual choices, and healthcare policies. As these medications become increasingly prevalent, addressing issues of affordability, equitable access, and long-term health implications will be crucial to ensuring that their benefits are realized by all who could benefit from them.